Immunome (IMNM) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Pipeline strategy and focus

• Pipeline centers on targeted oncology therapies, emphasizing cell surface and small molecule approaches, excluding cell therapy and CAR-T.

• Rigorous diligence process led to in-licensing of promising assets, with a focus on robust data and manufacturing capabilities.

• Infrastructure supports both antibody-based and small molecule drugs, enabling flexibility in pipeline expansion.

Desmoid tumor program and commercial outlook

• Gamma secretase inhibitor showed strong phase III results in desmoid tumors, with positive outcomes across all key endpoints.

• U.S. prevalence estimated at 11,000 patients seeking therapy annually, with a potential market exceeding 3,000 patients for blockbuster status.

• NDA submission targeted within months, with a record hazard ratio of 0.16 indicating high efficacy.

• Physicians value once-daily dosing, superior compliance, and pain relief compared to competitors.

• Medical affairs team expansion aims to support physician engagement and optimize real-world use.

Competitive positioning and launch plans

• Varegacestat offers higher objective response rates and once-daily dosing versus Ogsiveo, addressing compliance and pain management.

• Market entry strategy focuses on new and prevalent patients not responding to current therapies.

• Emphasis on medical affairs and post-approval studies to address physician needs and expand indications.

• NDA submission expected within four to six months of data readout, leveraging experienced regulatory and clinical teams.